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Abstract 
 
Background: Whether chronic inflammation increases prostate cancer risk remains unclear. This 
study investigated whether chronic inflammatory diseases (CID) or anti-inflammatory medication 
use (AIM) were associated with prostate cancer risk. 
Methods: 55,937 cases (all prostate cancer, 2007-2012) and 279,618 age-matched controls were 
selected from the Prostate Cancer Database Sweden. CIDs and AIMs was determined from national 
patient and drug registers. Associations were investigated using conditional logistic regression, 
including for disease/drug subtypes and exposure length/dose. 
Results: Men with a history of any CID had slightly increased risk of any prostate cancer diagnosis 
(OR: 1.08; 95%CI: 1.04-1.12) but not ‘unfavourable’ (high-risk or advanced) prostate cancer. 
Generally, risk of prostate cancer was highest for shorter exposure times. However, a positive 
association was observed for asthma >5 years before prostate cancer diagnosis (OR: 1.21; 95%CI: 
1.04-1.40). Risk of prostate cancer was increased with prior use of any AIMs (OR: 1.26; 95%CI: 1.24-
1.29). A positive trend with increasing cumulative dose was only observed for inhaled 
glucocorticoids (p<0.011). 
Conclusion: Detection bias most likely explains the elevated risk of prostate cancer with prior history 
of CIDs or use of AIMs, given the higher risk immediately after first CID event and lack of dose 
response.  However, findings for length of time with asthma and dose of inhaled glucocorticoids 
suggest that asthma may increase risk of prostate cancer through other pathways.  
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Background 
There is convincing evidence that some specific cancers are associated with chronic inflammatory 
diseases (CIDs). Examples include inflammatory bowel disease and colon cancer, Helicobacter Pylori 
infection and gastric cancer, hepatitis B and C infections and hepatocellular carcinoma [1]. Evidence 
for chronic inflammation as a risk factor for prostate cancer is less clear. Several different lines of 
evidence suggest that inflammation plays a role in prostate cancer development. For example, a 
number of putative risk factors for prostate cancer induce prostate inflammation, including 
heterocyclic amines in highly cooked meat, prostatitis and sexually transmitted diseases (STDs) [2-
4],[5]. In addition to localised inflammation, there is evidence suggesting systemic inflammation may 
also increase prostate cancer risk.  High levels of circulating C-reactive protein [6], a marker of 
inflammation, and increased Immunoglobulin (Ig) E levels [7], a marker of atopy, are associated with 
increased risk of prostate cancer. Increased risk of prostate cancer has been reported among men 
with asthma or other atopic conditions [8],[7] and among men with autoimmune diseases[9-12], 
though contradictory findings have also been reported [13-17]. On the other hand, reduced risk of 
prostate cancer has been reported with exposure to some anti-inflammatory medications (AIMs) 
used to manage CIDs, though again the evidence is mixed [18-21] 
  
However, previous evidence of positive associations between CIDs/AIMs and prostate cancer may be 
affected by detection bias, resulting from frequent health service encounters or investigations 
leading to detection of prostate cancer, especially for men with localised inflammation arising from 
prostatitis or STDs [22]. 
 
The aim of this study was to investigate the link between chronic inflammation and risk of prostate 
cancer by examining the association between 1) history of CIDs, and 2) use of AIMs, and prostate 
cancer incidence, using population-wide registry-based data. Our a priori hypotheses were that risk 
of prostate cancer would be increased among men with CIDs due to persistent or recurring exposure 
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to inflammatory mediators, while risk would be reduced among men who used AIMs, due to anti-
inflammatory properties of these drugs.  
 
Methods 
Data source and variables 
We used data from Prostate Cancer Database Sweden (PCBaSe), a population-wide database linkage 
to the National Prostate Cancer Registry (NPCR), the National Patient Register (NPR), the National 
Prescribed Drug Register (from Jan 1, 2006) and the Swedish longitudinal integration database for 
health insurance and labour market studies (LISA), through Swedish personal identification numbers 
[23]. In addition to men diagnosed with prostate cancer, PCBaSe also includes disease-free 
population controls, selected using an incident density sampling approach [23].The NPCR has near 
complete coverage (98%) of prostate cancer diagnoses across Sweden since 1988. Information 
collected in NPCR includes date of diagnosis, age, tumour stage and grade, levels of prostate specific 
antigen (PSA) at diagnosis, and primary treatment.  
 
We used a case-control design to study the association between CIDs/AIMs and risk of prostate 
cancer diagnosis.  The main outcome of this study was a diagnosis of prostate cancer, recorded in 
NPCR.  All men diagnosed with prostate cancer between Jan 1, 2007 and Dec 31, 2012 were selected 
as cases. Five population controls, free of prostate cancer at the time of diagnosis of the 
corresponding index case, matched on year of birth and area of residence, were selected for each 
case.  
 
The two broad exposures of interest were 1) prior history of CIDs and 2) exposure to AIMs.  For the 
CIDs component, the analytic study population was restricted to men diagnosed from 2007-2009 
plus controls, due to incomplete data on rare conditions from 2010 onwards. Prior history of CIDs 
was derived from International classification of diseases, 10th edition (ICD-10) codes recorded in the 
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NPR for any single hospital inpatient or outpatient episode from 1998 onwards. CIDs were classified 
into the following subcategories: chronic inflammatory and infectious diseases; allergies; and 
autoimmune diseases (further sub-grouped as auto-antibody negative; auto-antibody positive – 
systemic; and auto-antibody positive - organ specific diseases). Type 1 diabetes mellitus (T1DM) was 
excluded from the organ specific autoimmune category given likely misclassification of type 2 
diabetes mellitus.  Likewise, prostatitis was excluded from the chronic inflammatory diseases 
category due to likely detection bias from more intensive investigation of the prostate. Both were 
analysed separately. The full list of included diseases and respective ICD-10 codes is provided in the 
Supplementary Material.  
 
For analysis of AIMs, the whole study population was included. Exposure to selected AIMs was 
determined through linkage to Sweden’s National Prescribed Drug register, based on Anatomical 
Therapeutic Chemical (ATC) codes for drugs commonly prescribed for the management of CIDs: Non-
aspirin non-steroidal anti-inflammatory drugs (NSAID) (M01A), systemic glucocorticoids (H02AB), 
inhaled glucocorticoids (R03BA), non-steroidal asthma medications (R03AC, R03CC, R03AK, R03BB, 
R03DC), immuno-suppressants (L04A), and anti-gout medications (M04A). One previous prescription 
was considered to be sufficient to be classified as exposed. Data were extracted on class of drug, 
date of first prescription and cumulative dose before diagnosis. These data were only available from 
July 1, 2005, onwards. For both CIDs and AIMs, length of exposure and cumulative dose were 
determined for similar periods for cases and controls, with date of diagnosis of the case being used 
as the reference date for selected controls. 
 
Charlson comorbidity index [24] (CCI) was derived from data hospital admission records prior to 
diagnosis of Prostate cancer. Marital status and education level were extracted from LISA, while data 
on prostate cancer risk categories (grade, clinical stage, and prostate serum antigen (PSA) level at 
diagnosis) were extracted from NPCR. To determine whether CIDs or AIMs were associated with 
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disease severity at diagnosis we classified men with Prostate cancer according to risk categories. The 
‘favourable risk Prostate cancer’ group included low and intermediate risk categories (Gleason Score 
<=7, clinical stage T1-2, PSA≤20, N0/X and M0/X]), while the ‘unfavourable risk’ prostate cancer 
group included high-risk, regionally-advanced and metastatic disease (Gleason score=8-10, PSA>20, 
N1 or M1). These terms are used below to refer to different risk groupings. 
 
Statistical Analysis 
Associations between CIDs/AIMs and prostate cancer risk were examined using multivariable 
conditional logistic regression. Separate analyses were undertaken for any prior CIDs and any AIMs 
exposure, as well as each CID and AIM subtype. In all cases the reference group were all men not 
previously exposed to the specific condition or medication of interest. To assess the potential for 
detection bias, we examined length of time since first recorded diagnosis of CID (<12, 12-<36, 36-
<60, >=60 months) and total cumulative dose for subtypes of AIMs (<50, 50-<200, 200-<500, 500+ 
daily dose equivalents) prior to prostate cancer diagnosis. Models were adjusted for education level 
(low<10 years, middle 10-12 years, high>12 years); marital status (married, not married), and 
comorbidity (CCI =0, 1, 2, 3+). Wald tests were used to test trends according to categories of 
exposure for CIDs and cumulative daily dose for AIMs. Separate subgroup analyses were also 
undertaken restricted to ‘favourable’ and ‘unfavourable’ risk groups and their respective controls.  
We also investigated interaction between history of CIDs and major classes of anti-inflammatory 
medications.  For these analyses, interaction terms for CIDs and AIMs subtype were included in 
regression models for overall risk of prostate cancer, along with other covariates. Differences in log 
likelihood between models with and without interaction terms were used to determine any 
statistically significant effect modification in men with CID history. 
 
Finally we undertook a series of sensitivity analyse to examine the robustness of our findings with 
respect to AIMs and prostate cancer risk. These included 1) altering our definition of AIMs exposure 
   8 
 
to 2 or more prior prescriptions, 2) restricting the cohort to men diagnosed with prostate cancer 
from 2010-2012 to allow for longer time for AIMs exposure give prescription data were only 
available from 2006, and 3) excluding cases whose prostate cancer diagnosis was within 12months 
of their first prescription. 
 
All statistical analyses were undertaken using Stata v 14.0 (Stata Corporation, College Station, Texas 
USA). This study was approved by the Research Ethics Board, Umeå University, Sweden.  
 
Results 
The study population included 55,937 men with prostate cancer diagnosed between 2007 and 2012 
and 279,618 controls. Among cases, 32,193 (57%) had favourable risk prostate cancer, 22,275 (43%) 
had unfavourable risk prostate cancer, and 1469 (3%) had unknown risk category. Table 1 presents 
demographic characteristics of the study population. Mean age at diagnosis and selection as controls 
was 69 years (standard deviation=9). The proportion of men with a prior record of CIDs was similar 
between cases and controls (20% vs 19%). The proportion of men previously prescribed AIMs (all 
medications combined) was slightly higher for cases than controls (56% vs 50%).  
 
Chronic inflammatory conditions and prostate cancer risk 
Adjusted Risk ratios (ORs) for associations between history of CIDs and risk of prostate cancer are 
shown in Table 2. Results indicate a modest positive association between history of any CIDs and risk 
of prostate cancer (OR: 1.08; 95% CI 1.04-1.12). Positive associations were also observed for two 
disease sub-categories: chronic inflammatory/infectious diseases (OR: 1.07: 95%CI: 1.03-1.12) and 
allergies (OR: 1.10; 95%CI 1.03-1.18) and specifically for asthma within the allergies category (OR: 
1.13, 95%CI 1.02- 1.25). No association was observed for autoimmune diseases, including by 
antibody status or whether systemic or organ confined. We found moderately decreased risk of 
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prostate cancer among men with T1DM (OR: 0.71; 95%CI: 0.65-0.78) and elevated risk among men 
with chronic prostatitis (OR: 1.82; 95%CI: 1.53-2.16). 
 
Associations between CIDs and prostate cancer risk groups are also shown in Table 2. For all CIDs 
combined, and for the inflammatory/infectious diseases and allergies subcategories, risk was only 
increased for favourable risk prostate cancer. Only history of chronic prostatitis was associated with 
both favourable (OR: 2.03; 95%CI: 1.63-2.52) and unfavourable risk prostate cancer (OR: 1.56; 
95%CI: 1.18-2.07), with the former having the stronger association. The negative association 
observed for T1DM was evident for both favourable (OR: 0.64; 95%CI: 0.56-0.80) and unfavourable 
risk prostate cancer (OR: 0.80; 95%CI: 0.71-0.91), with a stronger association for favourable risk 
prostate cancer. 
 
Table 3 shows the adjusted ORs for CIDs and risk of prostate cancer for time since first recorded 
hospital episode. There were no consistent trends with length of time since first diagnosis for any 
CIDs or specific subtypes. For prostatitis, there was a significant decreasing trend in prostate cancer 
risk with increasing length of exposure (p=0.004). For the allergies subcategory, ORs were highest 
among men with their first hospital episode within 12 months of diagnosis (OR: 1.25; 95%CI:  1.00-
1.56), but were also elevated for intervals of more than 60 months (OR: 1.19; 95%CI:  1.05-1.28). The 
same pattern, though more pronounced, was seen for asthma alone.  
 
Anti-inflammatory medications and Prostate cancer risk 
A moderate positive association was observed for exposure to any of the listed AIMs (OR: 1.26; 
95%CI: 1.24-1.29) Table 4. Increased risk was observed for separate classes of AIMs including non-
aspirin-NSAIDs (OR: 1.25; 95%CI: 1.23-1.27); systemic glucocorticoids (OR: 1.14; 95%CI: 1.11-1.17), 
inhaled glucocorticoids (OR: 1.12; 95%CI: 1.08-1.17) and other non-steroidal asthma medications 
(OR: 1.11; 95%CI: 1.07-1.14). Of the non-aspirin-NSAIDs, risk of prostate cancer were elevated for 
   10 
 
acetic acid derivatives (OR: 1.24; 95%CI: 1.21-1.26), propionic acid derivatives (OR: 1.15; 95%CI: 
1.12-1.18) and Cox2 inhibitors (OR: 1.18; 95%CI: 1.12-1.21) and both short acting (OR: 1.09; 95%CI: 
1.03-1.16) and long acting beta agonist (OR: 1.12; 95%CI: 1.08-1.16) non-steroidal asthma 
medications. Sensitivity analyses with a stricter definition of exposure (≥2 prescriptions), with 
exclusion of cases diagnosed within 12 months of their first prescription and for the diagnosis period 
2010-12 did not alter the strength of direction of association for any AIMs subtypes and overall 
prostate cancer risk (Supplementary Table 1). 
 
With respect to disease severity, exposure to any AIMs was positively associated with both 
favourable (OR: 1.34; 95%CI: 1.31-1.38) and unfavourable risk prostate cancer (OR:  1.17; 95%CI: 
1.13-1.20) but associations were stronger for the favourable risk group. Similar patterns was 
observed for most AIMs subtypes.  
 
As shown in Table 5, significant trends indicating stronger associations with increasing cumulative 
dose were seen for inhaled glucocorticoids (p= 0.011) and immuno-suppressants (p=0.001).  
However, for immune-suppressants, lower cumulative doses (<=200 daily dose equivalents) were 
associated with reduced risk of prostate cancer diagnosis, with no association at higher doses (>200 
daily dose equivalents). For acetic acid derivatives there was a significant trend toward decreasing 
association with increasing cumulative dose (p=0.002). There were no significant trends for other 
classes of non-aspirin-NSAIDs. 
 
With respect to interaction between CIDs and AIMs, we observed a slight decrease in the strength of 
association between prior non-aspirin-NSAID use and overall prostate cancer risk among men with a 
history of CIDs (P<0.04).  Similar interactions were observed for acetic acid derivative (p=0.007) and 
for systemic glucocorticoid exposure (p=0.001) but again the effects was only slightly weaker in men 
with history of CIDs (Supplementary Table 2). 
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Discussion 
This comprehensive, population-wide observational study found no convincing evidence of 
increased risk of prostate cancer among men with a history of any CIDs. While the odds ratio for any 
prior CID was slightly elevated (OR=1.08), this only applied to favourable risk disease, with no 
elevated risk for less favourable risk prostate cancer. For specific CIDs, our results suggest increased 
risk of prostate cancer for chronic prostatitis and for allergies, but decreased risk among those 
hospitalised with T1DM. Our analyses of AIMs revealed moderately increase risk of prostate cancer 
with any use of AIMs, and specifically for non-aspirin-NSAID, glucocorticoids and other non-steroidal 
asthma medications.  
 
Detection bias most likely explains the association between prostate cancer and history of any CID or 
use of AIMs, given more frequent contact with the healthcare system would increase the 
opportunity for Prostate cancer detection through blood tests which include PSA measurement. As 
in most other countries, routine PSA screening is not recommended in Sweden [25]. Nevertheless, 
opportunistic screening occurs frequently in Sweden, with a 5-year prevalence estimated at 60% in 
2010 [26, 27]. Physicians attitudes and recommendations influence uptake of PSA testing [28, 29] 
and PSA testing frequency appears to be increased among those in regular contact with the 
healthcare system[30]. 
 
While several previous studies have reported associations between prostatitis and prostate cancer, 
debate is ongoing regarding whether the association is causal –i.e. via inflammatory pathways – or 
due to detection bias given more prostate-specific examinations [2]. Our results support the role of 
detection bias, since risk was highest for chronic prostatitis admissions within 12 months of 
diagnosis. However, given the elevated odds for chronic prostatitis >60 months prior to prostate 
   12 
 
cancer diagnosis, it is possible that other pathways may be involved, though this is difficult to 
disentangle from ongoing prostatic investigations. 
 
Previous studies have consistently reported lower risk of prostate cancer in men with diabetes [31-
34]. Proposed explanations include decreased hormone levels which may slow prostate 
carcinogenesis, potential effects of diabetes or anti-diabetic medications on serum PSA levels or 
prostate tissue pathology which lead to delays in diagnosis, and reduced screening/health seek 
behaviour among diabetic men which may reduce opportunities for diagnosis [34]. Though most of 
this evidence relates to type-2 diabetes mellitus, a multinational study using diabetes registry data 
has reported lower risk of prostate cancer among men with T1DM [35]. While our findings also 
suggest decreased risk in men with T1DM, concerns remain about the accuracy of hospital records 
for type of diabetes, given the higher than expected prevalence of T1DM in our cohort. 
 
With respect to allergies/asthma, we also observed higher risk for first hospitalisation within 12 
months, which indicates detection bias may play a role. However, risk was also significantly elevated 
for first hospitalisation >5years earlier suggesting the association may also involve pathways other 
than detection bias. Increased risk of prostate cancer has been reported previously among men with 
atopic diseases, specifically asthma [8], those using anti-asthma medications [21] and those positive 
for serum allergen-specific IgE, a marker of atopy [7]. However, the effect size in our study was more 
modest than other studies.   
 
Counter to expectations, we observed a positive association between use of AIMs and risk of 
prostate cancer, with the strongest effects for non-aspirin-NSAIDs. Given the association was only 
observed for favourable risk prostate cancer and there was no clear dose response, we again suspect 
this finding reflects detection bias.  While our findings are consistent with those of other large 
population-based studies (e.g. Skriver et al. 2016 [36], Denmark; Murad et al. 2011, UK [19]), they 
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are inconsistent with meta-analyses which conclude that there is no association [18, 37] or a 
negative association [20] between prostate cancer and use of non-aspirin-NSAIDs. The meta-analysis 
by Lui et al. however, did indicate a positive association between non-aspirin-NSAIDs and prostate 
cancer risk in studies undertaken in Europe.  Authors of the Danish population-based study also 
concluded that the positive association they observed was not likely to be causal [36]. However, 
findings from - studies on the use of non-aspirin-NSAIDs and prostate cancer risk within the context 
of PSA screening trials do not support effects due to detection bias alone [19, 38].  
 
With respect to inhaled glucocorticoids and prostate cancer risk we did find evidence of a dose-
response effect, suggesting there may be a causal relationship.  However, it is difficult to disentangle 
the effects of inhaled glucocorticoids from the effects of asthma, since most prescriptions would be 
for asthma. There are a number of plausible explanations for increased risk with frequent use of 
glucocorticoids. Firstly, immunosuppressive effect of glucocorticoids may weaken the body’s 
defence against nascent or developing tumours [39]. Secondly, metabolic changes induced through 
sustained use of glucocorticoids (i.e. metabolic syndrome, obesity, hyperglycaemia) have been 
linked to increased cancer risk [40]. Thirdly, glucocorticoids may directly impact prostate cancer 
development through ‘cross-talk’ signalling of androgen receptors, leading to upregulation of 
androgen pathways which stimulate prostate cell growth [41]. However, the lack of dose response 
with systemic glucocorticoids, and only a weak association with unfavourable risk prostate cancer 
lessen the argument for a causal relationship. Even if the association between inhaled 
glucocorticoids and prostate cancer was causal, the effect of prolonged use of these drugs is very 
modest and would not outweigh the benefits in terms of controlling asthma. 
 
We have used high-quality, registry-based databases to investigate the association between 
CIDs/AIMs and prostate cancer risk. In the context of autoimmune diseases, which are quite rare, 
having such a large study population and population-wide coverage is a major strength. 
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Furthermore, we were able to investigate dose-response relationships with respect to duration of 
CIDs and cumulative dose of AIMs. However, basing our exposure measure on hospital admission 
data will underestimate the true extent of CIDs since less severe inflammatory diseases (e.g. mild 
asthma, allergies) are often managed in community or outpatient settings. Likewise, prescription 
data may also be inaccurate since patients may not complete the course of medication prescribed.  
In addition we do not have information on prescription free NSAID use. Furthermore, many AIMs 
have broad application beyond the management of inflammatory conditions (though this does not 
nullify their effect on prostate cancer). In terms of timing of initial diagnosis of CIDs, hospital 
admission data from 1998 may provide too short a time window to completely capture CID history, 
since conditions may have diagnosed decades earlier. Even though we examined prostate cancer risk 
categories and trends according to exposure duration/dose, disentangling the effect of detection 
bias remains difficult without further information about primary health care visits and frequency of 
PSA testing.  
 
Conclusion 
This study found no consistent evidence linking prostate cancer risk to history of CIDs or use of AIMs. 
In general, the increased risk of prostate cancer is likely to be due to detection bias. However, 
findings suggesting possible associations with asthma/allergies and inhaled glucocorticoids warrant 
further investigation. More detailed clinical and translational research is required to better 
understand the relationship between chronic inflammation and prostate cancer risk, given 
limitations inherent in observational studies. 
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Table1. Characteristics of the study population 
Cohort Characteristics Cases  
n=55937 
Controls 
n=279618 
Age at diagnosis (years) No. (%) No. (%) 
<50 526 (1) 2656 (1) 
50-59 6716 (12) 33583 (12) 
60-69 22532 (40) 112544 (40) 
70-79 17582 (31) 87963 (31) 
80+ 8581 (15) 42872 (15) 
Marital status    
Single/divorced/widowed 18753 (34) 103830 (37) 
Married  37184 (66) 175788 (63) 
Education level   
<9yrs 20447 (37) 107490 (38) 
10-12yrs 21532 (38) 106261 (38) 
>12yrs 13532 (24) 61699 (22) 
missing 447 (1) 4168 (1) 
Charlson Comorbidity Index    
0 15268 (66) 73485 (64) 
1 3722 (17) 19636 (17) 
2 2369 (10) 11618 (10) 
3+ 1824 (7) 11169 (9) 
Period of diagnosis/inclusion   
2007-2009 27874 (50) 139311 (50) 
2010-2012 28963 (50) 140307 (50) 
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Table 2. Prior history of chronic inflammatory disease (CID) and odds of prostate cancer, overall and by disease categorya   
 
Prior record of chronic inflammatory diseaseb 
Controls 
n=139311 
Cases 
n=27874 
Overall PCa Favourable risk 
PCa 
Unfavourable 
risk PCa 
No. (%) No. (%) ORc (95% CI) ORc (95% CI) ORc (95% CI) 
      
Any chronic inflammatory /autoimmune disease 
 (excl. prostatitis and T1DM) 
26272 (19) 5460 (20) 1.08 (1.04-1.12) 1.13 (1.08-1.19) 1.02 (0.96-1.07) 
Chronic inflammatory / infectious diseases (excl. Prostatitis) 17027 (12) 3520 (13) 1.07 (1.03-1.12) 1.10 (1.04-1.16) 1.05 (0.99-1.11) 
       Chronic prostatitis 492 (0.4) 180 (0.7) 1.82 (1.53-2.16) 2.03 (1.63-2.52) 1.56 (1.18-2.07) 
Allergies (including Asthma) 5064 (4) 1084 (4) 1.10 (1.03-1.18) 1.22 (1.12-1.33) 0.97 (0.87-1.07) 
       Asthma alone 2116 (2) 456 (2) 1.13 (1.02-1.25) 1.22 (1.07-1.41) 1.03 (0.88-1.20) 
Autoimmune diseases (any excluding T1DM): 7692 (5) 1542 (6) 1.03 (0.97-1.09) 1.07 (0.99-1.15) 0.98 (0.90-1.07) 
Autoantibody negative 5349 (4) 1103 (4) 1.05 (0.98-1.12) 1.08 (0.99-1.18) 1.00 (0.90-1.10) 
Autoantibody positive  - systemic 1464 (1) 296 (1) 1.07 (0.94-1.21) 1.07 ( 0.90-1.28) 1.06 (0.89=1.27) 
Autoantibody positive  - organ specific 5221 (4) 774 (3) 0.77 (0.71-0.83) 0.74 (0.67-0.83) 0.82 (0.73-0.91) 
Autoantibody positive  - organ specific (excl. T1DM) 1152 (1) 220 (1) 0.98 (0.84-1.12) 1.08 (0.89-1.31) 0.85 (0.68-1.06) 
       T1DM 4136 (3) 506 (2) 0.71 (0.65-0.78) 0.64 (0.56-0.73) 0.80 (0.71-0.91) 
      
 
Aberrations: CI: confidence interval, OR: Odds Ratio, PCa: prostate cancer, T1DM: Type 1 diabetes mellitus 
a Favourable risk PCa: low and intermediate risk (Gleason Score≤7, T1-T2, PSA≤20ng/mL, N0/X, & M0/X), Unfavourable risk PCa: (Gleason score 8-10, or PSA>20ng/ml, or N1, or M1) 
b Derived from ICD-10 diagnosis codes recorded in hospital admission or outpatient records since 1997. Reference category = no record of inpatient or outpatient hospital episode.  
c Adjusted OR from conditional logistic regression with adjustment for civil status, education level and Charlson Comorbidity Index. Analyses stratified low/intermediate risk and advanced 
disease at diagnosis along with respective matched controls. Analysis undertaken on subset diagnosed 2007-09, with complete hospital admission data from Jan 1, 1997 – Dec 31, 2009 
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Table 3. Time interval from first recorded episode for specific inflammatory disease groups and odds of prostate cancer diagnosis 
 
Time from first hospital episode to 
diagnosis/inclusion date  
<12 months 12-<36 months ≥ 36 months >60 months  
ORa (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) p-trendb 
 DISEASE GROUPS (reference: no recorded episode)      
Any chronic inflammatory /autoimmune disease 
 (excl. prostatitis and T1DM) 
1.01 (0.90-1.14) 1.09 (1.02-1.16) 1.04 (0.98-1.11) 1.10 (1.05-1.15) 0.371 
Chronic inflammatory/infectious diseases  
(excl. prostatitis) 
0.93 (0.80-1.07) 1.11 (1.03-1.20) 1.07 (1.03-1.12) 1.10 (1.04-1.16) 0.390 
      Chronic Prostatitis  3.93 (2.15-7.19) 2.29 (1.66-3.16) 1.52 (1.23-1.89) 1.53 (1.15-2.03) 0.004 
Allergies (including asthma) 1.25 (1.00-1.56) 1.01 (0.88-1.15) 1.04 (0.91-1.19) 1.19 (1.05-1.28) 0.480 
       Asthma alone 1.63 (1.14-2.31) 0.94 (0.74-1.18) 0.99 (0.79-1.23) 1.21 (1.05-1.40) 0.700 
Auto-immune diseases (excluding T1DM) 1.05 (0.84-1.32) 0.96 (0.85-1.09) 1.03 (0.91-1.16) 1.05 (0.97-1.13) 0.425 
      Antibody negative 1.13 (0.87-1.46) 0.98 (0.85-1.13) 1.12 (0.98-1.28) 1.03 (0.94-1.14) 0.981 
      Antibody positive - systemic 0.92 (0.53-1.59) 1.01 (0.76-1.34)) 0.99 (0.74-1.33) 1.13 (0.96-1.33) 0.303 
      Antibody positive - organ confined (excl. T1DM) 0.90 (0.47-1.69) 1.01 (0.74-1.37) 0.70 (0.48-1.03) 1.06 ( 0.87-1.27) 0.474 
      T1DM only 0.97 (0.68-1.40) 0.66 (0.53-0.81) 0.71 (0.64-0.79) 0.71 (0.63-0.81) 0.673 
      
 
 
Aberrations: CI: confidence interval, OR: Odds Ratio, PCa: prostate cancer, T1DM: Type 1 diabetes mellitus 
a Adjusted OR from conditional logistic regression with adjustment for marital status, education level and Charlson Comorbidity Index. Analysis undertaken on subset diagnosed 2007-09, with 
complete hospital admission data from Jan 1, 1997 – Dec 31, 2009 
b P-value for trend across time categories (Wald statistic) 
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Table 4. Prior exposure to anti-inflammatory medications and the odds of prostate cancer, overall and by disease categorya   
 
Exposure anti-inflammatory medicationsb 
Controls 
n=279618 
Cases   
n=55937 
Overall PCa Favourable risk 
PCa 
Unfavourable risk 
PCa  
No. % No. % ORc (95% CI) ORc (95% CI) ORc (95% CI) 
Any Anti-inflammatory medication 141172 (50) 31330 (56) 1.26 (1.24-1.29) 1.34 (1.31-1.38) 1.17 (1.13-1.20) 
Any Non-Aspirin-NSAIDs 112742 (40) 25591 (46) 1.25 (1.23-1.27) 1.33 (1.30-1.36) 1.15 (1.12-1.19) 
Acetic acid derivatives 79279 (28) 18332 (33) 1.24 (1.21-1.26) 1.29 (1.26-1.33) 1.16 (1.12-1.20) 
Propionic acid derivatives 43766 (16) 9817 (18) 1.15 (1.12-1.18) 1.22 (1.18-1.26) 1.07 (1.03-1.11) 
Cox inhibitors  7741 (3) 1828 (3) 1.18 (1.12-1.25) 1.24 ( 1.16-132) 1.10 ( 1.01-1.20) 
Oxicams 2085 (1) 456 (1) 1.09 (0.98-1.21) 1.24 (1.09-1.41) 0.87 (0.73-1.04) 
Other non-Aspirin NSAIDs 15093 (5) 3334 (6) 1.10 (1.06-1.14) 1.25 (1.19-1.32) 0.92 (0.87-0.98) 
Any non-topical glucocorticoid  43052 (15) 9500 (17) 1.14 (1.11-1.17) 1.19 (1.15-1.23) 1.08 (1.04-1.12) 
Systemic glucocorticoids 33616 (12) 7449 (13) 1.14 (1.11-1.18) 1.20 (1.16-1.25) 1.08 (1.03-1.12) 
Inhaled glucocorticoids 15111 (5) 3343 (6) 1.12 (1.08-1.17) 1.15 (1.09-1.21) 1.09 (1.03-1.15) 
Any (nonsteroidal) asthma medications  23205 (8) 4948 (9) 1.11 (1.07-1.14) 1.12 (1.07-1.17) 1.09 (1.03-1.14) 
Short term b-agonists 6171 (2) 1302 (2) 1.09 (1.03-1.16) 1.10 (1.02-1.20) 1.07 (0.98-1.17) 
Long term b-agonists 17840 (6) 3850 (7) 1.12 (1.08-1.16) 1.11 (1.06-1.17) 1.12 (1.06-1.18) 
LAMA 7202 (3) 1441 (3) 1.06 (1.00-1.12) 1.06 (0.98-1.15) 1.05 (0.97-1.14) 
LTRAs 1579 (1) 340 (1) 1.08 (0.96-1.21) 1.10 (0.95-1.28) 1.05 (0.87-1.27) 
Anti-Gout medications 12910 (5) 2568 (5) 1.03 (0.98-1.07) 1.00 (0.94-1.07) 1.05 (0.99-1.12) 
Immuno-suppressants 4281 (2) 812 (1) 0.98 (0.91-1.06) 0.98 (0.88-1.08) 1.00 (0.89-1.13) 
      
 
CI: confidence interval, LAMA: long acting muscarinic antagonists; LTRAs: leukotriene receptor antagonists; NSAIDs: non-steroidal anti-inflammatory drugs, OR: odds ratio 
a Favourable risk PCa: low and intermediate risk (Gleason Score≤7, T1-T2, PSA≤20ng/mL, N0/X, & M0/X), Unfavourable risk PCa: (Gleason score 8-10, or PSA>20ng/ml, or N1, or M1) 
b Any exposure to anti-inflammatory medications since July 2005, derived from the National Prescribed Drug Register based on anatomical therapeutic chemical (ATC) codes 
c Adjusted OR from conditional logistic regression with adjustment for marital status, education level and Charlson comorbidity index. Analysis undertaken in the full dataset (2007-2012). 
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Table 5. Cumulative dose for selected classes of anti-inflammatory medications and risk of prostate cancer 
 
Cumulative dose of  
anti-inflammatory medication a 
<=50 dd 51-200 dd 201-500  dd >500 dd  
ORb (95% CI) ORb (95% CI) ORb (95% CI) ORb (95% CI) p-trendc 
      
Any na-NSAID (reference: no prescriptions) 1.20 (1.18-1.23) 1.34 (1.30-1.37) 1.29 (1.24-1.35) 1.19 (1.14-1.24) 0.078 
     Acetic acid derivatives 1.20 (1.17-1.22) 1.33 (1.29-1.38) 1.27 (1.20-1.36) 1.19 (1.09-1.30) 0.002 
     Propionic acid derivatives 1.15 (1.11-1.18) 1.20 (1.15-1.26) 1.14 (1.06-1.22) 1.06 (0.99-1.14) 0.226 
     Cox inhibitors 1.20 (1.12-1.29) 1.20 (1.09-1.32) 1.24 (1.04-1.47) 0.94 (0.76-1.15) 0.128 
Systemic glucocorticoids 1.12 (1.08-1.17) 1.17 (1.11-1.23) 1.24 (1.15-1.32) 1.08 (1.01-1.16) 0.697 
Inhaled glucocorticoids 1.03 (0.95-1.12) 1.09 (1.02-1.17) 1.23 (1.13-1.34) 1.16 (1.08-1.24) 0.011  
Non-steroidal asthma medications 1.06 (0.99-1.14) 1.06 (0.99-1.14) 1.17 (1.09-1.26) 1.12 (1.07-1.18) 0.098 
Immuno-suppressants 0.58 (0.38-0.89) 0.75 (0.60-0.92) 1.02 (0.86-1.21) 1.06 (0.96-1.17) 0.001 
      
 
CI: confidence interval, dd: daily dose equivalents; NSAIDs: non-steroidal anti-inflammatory drugs, OR: odds ratio 
a Cumulative daily dose equivalents of specific anti-inflammatory medications since July 2005, derived from the National Prescribed Drug Register based on anatomical therapeutic chemical 
(ATC) codes 
b Adjusted odds ratios derived from conditional logistic regression with adjustment for civil status, education level and Charlson comorbidity index. Analysis undertaken in the full dataset 
(2007-2012). 
c P-value for trend across cumulative dose categories (Wald statistic) 
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APPENDIX: LIST OF CONDITIONS AND MEDICATIONS INCLUDED AS EXPOSURES 
 
Included inflammatory conditions (ICD 10 Codes): 
Chronic inflammatory or infectious diseases: chronic  sinusitis (J32), chronic diseases tonsils (J35),  chronic 
laryngitis (J37), chronic bronchitis (J41, J42), emphysema /chronic obstructive pulmonary disease (J43, J44), 
bronchiectasis (J47), chronic thyroiditis (E06.2, E06.5), gout (M10), osteoarthritis (M15-M19), reactive arthritis 
(M02.8), other polyarthritis (M13.0), chronic periodontitis (K05.3, K04.5), chronic gingivitis (K05.1), chronic 
pancreatitis (K86.0, K86.1), Chronic hepatitis (K71.3-K71.9, K72.9,  K73, K75.4), chronic viral hepatitis (B18), 
chronic cholecystitis (K81.1), ulcerative colitis (K25.5-K25.9, K26.4-K26.9, k28.4-k28.9, K29.4-k29.9), chronic 
nephritis/nephrotic syndrome (N03-N04, N011), chronic cystitis (N30.1-N31.2), pemphigus (L10),  diverticulitis 
(K57), chronic pericarditis (I31.0-I31.1), myositis (M60), chronic osteitis/osteomyelitis (M85.3, M85.3, M86.3-
M86.6), vasculitis M31.0, M31.4, M31.5) 
Allergies:  allergic rhinitis (J30, J31), asthma (J45), urticaria (L50), erythema nodosum (L52), atopic dermatitis 
(L20, L23), eosinophilic esophagitis (K20.0) 
Systemic autoantibody positive autoimmune: rheumatoid arthritis (M05, M06), systemic lupus 
erythematosus (M32), dermatomyositis/polymyositis (M33), systemic sclerosis (M34), Sicca/Sjogren’s (M35.0), 
systemic vasculitis (M35.9). 
Organ specific autoantibody autoimmune:  autoimmune thyroiditis (E06.3), autoimmune hepatitis (K74.4), 
chronic rheumatic heart disease (I05-I09), Multiple Sclerosis (G35), Addison’s Disease (E27.1), Immune 
thrombocytopenic purpura (D69.3), Primary biliary cirrhosis (K74.3, Discord lupus erythematosus (L93.0), 
Localised scleroderma (L94.0), myasthenia gravis (G70.0), polyarteritis nodosa (M30), Guillian-Barre Syndrome 
Polyneuropathy (G61.0), Celiac Disease (K90.0), amyotrophic lateral sclerosis (G12.23), polyangiitis with 
granulomatosis (M31.3), Raynaud’s disease (I73.0). 
Autoimmune autoantibody negative: Non-infective Enteritis Colitis (K50 – K52), sarcoidosis (D86), Behcet 
(M35.2), Polymyalgia rheumatic (M35.3) , Ankylosing spondylitis (M45-M46), enteropathic arthritis (M07), 
Vitiligo (L80), Psoriasis (L40), Giant cell arteritis (M31.5, M31.6), Reactive Arthritis (M02.3) 
Note: Chronic prostatitis (N41.1) was excluded from the chronic inflammatory disease group due to concern 
about the high potential for detection bias. 
Type 1 Diabetes (E10) was excluded from the organ specific autoantibody autoimmune disease group due to 
uncertainty about the accuracy of coding.  
 
Included anti-inflammatory medications (ATC codes): 
Non-Aspirin Non-Steroidal Anti-inflammatory Drugs: (M01A) 
Butypyrazolidines(M01AA); acetic acid derivatives (M01AB); Oxicams (M01AC); Propionic acid derivatives 
(M01AE); Fenamates (M01AG); Coxibs (M01AH); other non-aspirin-NSAIDs (M01AX) 
Immuno-suppressants (L04A) 
Systemic glucocorticoids (H02AB) 
Inhaled glucocorticoids (R03BA) 
Non-steroidal anti-asthma medications: Short term b-agonists (R03AC02, R03CC03, R03CC53), Long term b-
agonists (R03AK06, R03AK07, R03AK08, R03AK10, R03AK11, R03AC12, R03AC13, R03AC18, R03AC19, 
R03CC12), long acting muscarinic antagonists (R03BB04, R03BB06, R03BB07), Leukotriene receptor antagonists 
(R03DC03, R03DC01) 
Anti-Gout medications (M04A) 
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Supplementary Table 1. Adjusted Odds for association between AIMs exposure and PCa diagnosis in sensitivity analyses  
a) AIMs exposure defined as ≥2 prescriptions prior to diagnosis 
b) Analysis to PCa diagnoses in 2010 – 2012 only 
c) First prescription within 12 months of diagnosis excluded from analysis 
 
Cumulative dose of  
anti-inflammatory medication a 
AIMs defined as     
2+ prescriptions 
Restricted to PCa   
Dx 2010-2012 
1st prescription 
>12m before PCa Dx 
ORb (95% CI) ORb (95% CI) ORb (95% CI) 
    
Any na-NSAID (reference: no prescriptions) 1.27 (1.22-1.30) 1.23 (1.20-1.26) 1.29 (1.27-1.32) 
     Acetic acid derivatives 1.21 (1.16-1.40) 1.20 (1.16-1.23) 1.24 (1.21-1.26) 
     Propionic acid derivatives 1.13 (1.07-1.19) 1.13 (1.09- 1.17) 1.12 (1.09-1.25) 
     Cox inhibitors 1.15 (1.02-1.28) 1.18 (1.10-1.26) 1.14 (1.08-1.22) 
Systemic glucocorticoids 1.19 (1.14-1.23) 1.14 (1.10-1.18) 1.10 (1.07-1.13) 
Inhaled glucocorticoids 1.18 (1.13-1.23) 1.09 (1.03-1.14) 1.13 (1.08-1.18) 
Non-steroidal asthma medications 1.07 (0.96-1.20) 1.09 (1.03-1.15) 1.08 (1.04-1.12) 
Immuno-suppressants 1.02 (0.94-1.10) 1.00 (0.91-1.12) 0.98 (0.91-1.07) 
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Supplementary Table 2 Interaction between CID and AIM exposure in relation to overall risk of PCa diagnosis 
Interaction between any CID* and AIMs Interaction between CIDs and AIMS 
 Ratio of ORs (95% CI) P-value  
(reference: no prescription for relevant medication)   
Any na-NSAID  0.93 (0.87-1.00) 0.040 
     Acetic acid derivatives 0.91 (0.84-0.97) 0.007 
     Propionic acid derivatives 1.03 (0.94-1.12) 0.493 
     Cox inhibitors 0.97 (0.80-1.16) 0.735 
Systemic glucocorticoids 0.86 (0.79-0.94) 0.001 
Inhaled glucocorticoids* 0.90 (0.76-1.06) 0.198 
Non-steroidal asthma medications* 0.99 (0.86-1.15) 0.930 
Immuno-suppressants 0.97 (0.68-1.37) 0.874 
   
*Interaction with asthma/allergies rather than any CID for respiratory glucocorticoids and non-steroidal asthma medications. 
 
